Phase I study of liposomal annamycin

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• Annamycin is a lipophilic anthracycline designed to overcome multidrug resistance (MDR-1).
• Liposomal encapsulation enhances drug delivery and potentially alters pharmacokinetic profiles.
• Relapsed solid tumors often present challenges due to acquired cellular drug resistance.

Purpose of the Study:

• To evaluate the safety and tolerability of liposomal annamycin in patients with relapsed solid tumors.
• To determine the maximum tolerated dose (MTD) of liposomal annamycin.
• To assess the pharmacokinetic profile of liposomal annamycin.

Main Methods:

• Phase I clinical trial enrolling 36 patients with relapsed solid tumors.
• Intravenous infusion of liposomal annamycin at escalating doses (3-240 mg/m2) every 3 weeks.
• Monitoring for dose-limiting toxicities, including cardiac function via endomyocardial biopsy, and pharmacokinetic analysis.

Main Results:

• Thrombocytopenia was identified as the dose-limiting toxicity.
• The maximum tolerated dose (MTD) was determined to be 210 mg/m2.
• No significant cardiac toxicity, alopecia, or severe gastrointestinal toxicity was observed; limited allergic reactions occurred.

Conclusions:

• Liposomal annamycin demonstrates a manageable safety profile in patients with relapsed solid tumors.
• The MTD of 210 mg/m2 was established, with a revised MTD of 190 mg/m2 for future studies due to formulation changes.
• Further investigation is warranted, although no objective tumor responses were noted in this phase I study.